semaglutide ingredients | C187H291N45O59 | CID 56843331 💉Although many of the names

[DOI] [PMC free article] [PubMed] [Google Scholar] Barreiro C

Xolair (Roche): $3.7B US sales in 2025, losing exclusivity now after 23 years Only Celltrion has an approved biosimilar ready Pomalyst (BMS): $2.34B US sales at risk One of many drugs losing patent protection from BMS recently/upcoming Opsumit (J&J): $1.63B US sales Already facing direct competition from Merck's Winrevair 10 generic manufacturers are ready to go with FDA approval Januvia/Janumet (Merck): $1.27B US sales 25+ generic settlements already in place Also losing US exclusivity: Simponi (J&J): $1.19B - autoimmune TNF blocker Mavenclad (Merck KGaA): $716M - relapsing MS Gattex (Takeda): $707M - short bowel syndrome Trintellix (Takeda): $698M - major depressive disorder Briviact (UCB): $652M - epilepsy Xeljanz (Pfizer): $625M - rheumatoid arthritis --- Patent expiry doesn't necessarily mean competition

"You have no way of actually knowing as an American patient if you're getting the real deal or if you're getting a counterfeit, because it's really easy to lie on the internet and it's super easy to counterfeit a drug," Baney said

Lancet 2: 1300-1304, 1987

It is marketed under the brand names Wegovy, specifically for weight management, and Ozempic, approved for type 2 diabetes

All PlexusDx semaglutide comes from licensed 503A compounding pharmacies and is available in all 50 states without insurance or membership fees